Short Interest in BioRestorative Therapies, Inc. (NASDAQ:BRTX) Expands By 68.3%

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a significant increase in short interest in November. As of November 15th, there was short interest totalling 74,400 shares, an increase of 68.3% from the October 31st total of 44,200 shares. Based on an average trading volume of 25,900 shares, the short-interest ratio is presently 2.9 days. Approximately 1.5% of the company’s shares are sold short.

BioRestorative Therapies Stock Performance

Shares of BRTX traded up $0.05 during trading hours on Friday, hitting $1.53. The company had a trading volume of 4,837 shares, compared to its average volume of 736,430. The firm has a fifty day moving average price of $1.60 and a 200-day moving average price of $1.60. The stock has a market capitalization of $10.59 million, a price-to-earnings ratio of -1.00 and a beta of 63.40. BioRestorative Therapies has a 52-week low of $1.03 and a 52-week high of $3.67.

BioRestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.22. The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.30 million. BioRestorative Therapies had a negative return on equity of 98.49% and a negative net margin of 2,697.08%. Research analysts anticipate that BioRestorative Therapies will post -1.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Roth Mkm boosted their target price on shares of BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, August 14th.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.